CJC-1295 DAC vs No-DAC: Same Peptide, Two Release Patterns (2026)
CJC-1295 with DAC and CJC-1295 without DAC are built on the exact same core peptide, modified GRF 1-29, so the honest headline is that this is not a fight between two different molecules. It is a decision about one piece of technology: the Drug Affinity Complex (DAC), a small chemical add-on that binds the peptide to albumin and stretches its half-life from about 30 minutes to roughly a week. Strip the jargon and the choice is simple to frame: do you want a steady, weeklong "GH bleed" with one or two injections (DAC), or sharp daily pulses that mimic your body's natural rhythm at the cost of injecting every day (no-DAC)?
Most "DAC vs no-DAC" pages bury that single fact under a feature table. We lead with it, then answer the question the search actually carries: which release pattern is better, and which one the research community actually leans on. For the full pharmacology of the CJC-1295 molecule itself, and for the popular CJC-1295 plus ipamorelin stack that ranks among the most-used peptides for muscle growth, we link out so this page stays a clean format-decision hub.
Head-to-head
Edge: CJC-1295 without DAC — by a modest margin
This is a same-molecule, two-format comparison: CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) share the same modified GRF 1-29 core peptide; the only difference is the Drug Affinity Complex (DAC), a half-life-extension technology. The honest decision: if you want growth-hormone release that mimics the body's natural pulses, the no-DAC form edges it (half-life ~30 minutes, sharp pulsatile release, lower theoretical desensitization risk) and is the convention most of the research community leans on, which is why it scores slightly higher here (60 vs 53). DAC wins on convenience alone (one or two injections a week instead of one to three a day) by holding GH and IGF-1 tonically elevated for days. Both are research peptides, not FDA-approved, with no human body-composition efficacy trials. The moat is a secondary signal only: there is no head-to-head switch data between two forms of one peptide, but ProtocolPlus tracks roughly 768 CJC-1295 users, and the small-daily no-DAC dosing convention dominates that logging.
Overall fit score
By dimension
Side by side
| CJC-1295 with DAC | CJC-1295 without DAC | |
|---|---|---|
| Core peptide | Modified GRF 1-29 (same molecule) | Modified GRF 1-29 (same molecule) |
| Half-life technology | Drug Affinity Complex (DAC); binds serum albumin | None; unmodified short-acting GHRH analog |
| Half-life | ~6-8 days (5.8-8.1 d, Teichman 2006) | ~30 minutes (up to ~1-2 h) |
| GH-release pattern | Sustained / tonic - GH and IGF-1 elevated continuously for days | Pulsatile - sharp transient GH bursts that mimic natural rhythm |
| Dosing frequency | 1-2 injections per week | 1-3 injections per day |
| Main physiologic concern | Non-physiologic steady elevation; theoretical pituitary blunting / receptor desensitization | Preserves pulsatility; main burden is daily-injection logistics |
| Route | Subcutaneous injection (research use) | Subcutaneous injection (research use) |
| Regulatory status | Research peptide; not FDA-approved; no human efficacy trials | Research peptide; not FDA-approved; no human efficacy trials |
Educational. These are research compounds, not FDA-approved, with limited or no human trial data. Not medical advice and not a claim either is effective or safe. Community figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- Same core peptide, two formats. Both are modified GRF 1-29. The only difference is the DAC half-life-extension technology bolted onto one of them. Mod GRF 1-29 and "CJC-1295 no-DAC" are two names for the same thing.
- DAC = steady and convenient. The albumin-binding DAC gives a ~6-8 day half-life, so one to two injections a week hold growth hormone and IGF-1 elevated continuously.
- No-DAC = pulsatile and physiologic. A ~30-minute half-life produces a sharp, transient GH pulse that mimics natural bursts, but it has to be injected one to three times a day.
- The real debate is steady vs pulsatile. Critics argue the DAC form's non-stop GH elevation is non-physiologic and may blunt natural pulses or desensitize the pituitary over time; the no-DAC form preserves the body's rhythm. That, plus convenience, is the whole trade-off.
- Neither is proven in humans. There are no human efficacy trials for body composition; the only controlled human data is an early pharmacology study (Teichman 2006). Both are research-only and not FDA-approved.
- The community leans no-DAC. In our data the CJC-1295 usage convention is dominated by small, frequent (no-DAC-style) dosing, usually stacked with a GHRP like ipamorelin.
Steady vs pulsatile: the one chart that frames the whole decision
Here is the difference made visual. CJC-1295 with DAC holds growth hormone elevated as a near-flat plateau for days; CJC-1295 without DAC creates a sharp spike that rises and falls within a couple of hours, the way the pituitary releases GH naturally. Everything else in this article is downstream of this single contrast.
CJC-1295 DAC vs no-DAC at a glance
The table makes the structure obvious: the core peptide is identical, and so is the route and the research-only legal status. What differs is the half-life technology, and everything that flows from it, dosing frequency and release pattern.
| Dimension | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Core peptide | Modified GRF 1-29 | Modified GRF 1-29 (identical) |
| Half-life technology | Drug Affinity Complex (binds albumin) | None (unmodified) |
| Half-life | ~6-8 days | ~30 minutes |
| GH-release pattern | Sustained / tonic | Pulsatile (mimics natural) |
| Dosing frequency | 1-2x per week | 1-3x per day |
| Main concern | Non-physiologic steady elevation | Daily-injection burden |
| Route | Subcutaneous (research use) | Subcutaneous (research use) |
| Status | Research peptide, not FDA-approved | Research peptide, not FDA-approved |
The one fact that settles most of this: it is the same peptide
The single most important thing to understand is that CJC-1295 without DAC and modified GRF 1-29 are the same molecule under two names, and CJC-1295 with DAC is that same modified GRF 1-29 with one extra chemical handle. Both are analogs of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary to release growth hormone. They bind the same GHRH receptor and trigger the same downstream event. The DAC is not a different drug; it is a delivery technology.
DAC stands for Drug Affinity Complex. Mechanically, it is a maleimidoproprionic-acid group added to the peptide that lets it bond to circulating serum albumin, a plasma protein that shields the peptide from the enzymes that would normally chew it up in minutes. That single modification is what turns a ~30-minute half-life into one measured in days. So when people ask "which is better for growth hormone release," they are really asking "do I want that release delivered as a steady plateau or as natural-looking pulses," because the peptide doing the releasing is the same in both. For the full pharmacology of how the molecule acts on the GHRH receptor, see the CJC-1295 guide.
The steady-vs-pulsatile debate, properly
The one-sentence answer: the case against DAC is that constantly elevated growth hormone is not how the body works, and the case for it is that it is far more convenient. That tension is the heart of the whole DAC-vs-no-DAC argument, so it is worth laying out honestly rather than picking a side by reflex.
Your body does not secrete growth hormone in a steady stream. It releases it in bursts, mostly at night, with low troughs in between, and that pulsatility appears to matter: the troughs may be part of what keeps the system responsive. The no-DAC camp argues that a ~30-minute pulse respects this rhythm, while the DAC form's multi-day plateau is non-physiologic and could, in theory, blunt the pituitary's own pulses or drift toward receptor desensitization with prolonged use. It is a mechanistically reasonable concern.
The honest caveat is that this is a theoretical and mechanistic argument, not a proven clinical outcome. There are no human trials measuring whether DAC's steady elevation actually desensitizes anything or produces worse real-world results than pulsatile no-DAC dosing over time; the desensitization worry is extrapolated from how continuous versus pulsatile hormone signaling behaves in general, not from a head-to-head study of these two forms. So the fair framing is: the no-DAC form has the more physiologic profile on paper and that is a real point in its favor, but "more physiologic" is a plausibility argument, not demonstrated superiority. The DAC form's counter-argument, that weekly dosing is the only schedule many people will actually adhere to, is also legitimate.
There is even a data point that complicates the simple version of the desensitization story. A companion 2006 analysis by Ionescu and Frohman found that the pituitary's own pulsatile GH secretion persisted during continuous stimulation by CJC-1295 with DAC, rather than being flattened out entirely. In other words, the steady "GH bleed" raises the baseline that the natural pulses ride on top of, instead of abolishing the pulses. That nuance cuts against the strongest version of the "DAC destroys your rhythm" claim while still leaving the broader worry, sustained elevated IGF-1 and a higher tonic GH floor, intact. It is a good example of why this whole debate deserves humility: the mechanism is genuinely interesting, the long-term consequences in real users are simply unstudied, and confident verdicts in either direction are overstated.
What the human data actually shows (and what it does not)
The one-sentence answer: the only controlled human evidence is an early-phase pharmacology study of the DAC form, and it measured hormone levels, not body composition or any outcome people actually want. In a 2006 Phase 1 trial published in the Journal of Clinical Endocrinology & Metabolism, Teichman and colleagues gave healthy adults single subcutaneous doses of CJC-1295 with DAC and reported dose-dependent mean growth hormone elevations of roughly 2- to 10-fold and IGF-1 elevations of about 1.5- to 3-fold above baseline. After repeat dosing, mean IGF-1 stayed above baseline for up to 28 days, and the estimated half-life landed at 5.8 to 8.1 days.
That study is the source of every "6-8 day half-life" and "sustained GH/IGF-1" claim you will read, including on this page. But be clear about its limits. It was a small, early-phase pharmacology and safety study; it demonstrated that the DAC form raises GH and IGF-1 and does so for days, and that is all. It did not measure fat loss, muscle gain, recovery, sleep, or anti-aging. There is even less controlled human data for the no-DAC form specifically, and effectively none comparing the two head to head. So when anyone tells you one form "builds more muscle" or "is better for cutting," they are reasoning from mechanism and anecdote, not from trials, because the trials do not exist. Any doses you see are reported as studied or as community convention, never as a recommendation to follow.
Dosing and the GHRP stack: where no-DAC earns its following
The one-sentence answer: the no-DAC form's short pulse is usually timed to specific moments and paired with a growth-hormone-releasing peptide (GHRP) like ipamorelin, which is a big part of why the research community converged on it. Because a no-DAC pulse rises and clears within a couple of hours, it is conventionally injected at times when a natural GH pulse is welcome, classically before sleep and away from food, often one to three times a day.
The synergy story is the real draw. GHRH analogs (like CJC-1295) and GHRPs (like ipamorelin) act on two different receptors and amplify each other: the GHRH analog increases the amount of GH released per pulse, while the GHRP both triggers a pulse and blunts somatostatin, the brake on GH. Stacking a short-acting no-DAC GHRH analog with a short-acting GHRP produces a clean, large, physiologic pulse, then lets everything fall back to baseline, exactly the rhythm the pulsatile camp wants to preserve. A multi-day DAC plateau does not layer onto a discrete GHRP pulse the same way, which is the mechanistic reason most stack protocols specify the no-DAC form.
This is also where the timing burden of no-DAC stops looking like a pure downside. Because the pulse and its GHRP partner clear within a couple of hours, you get to choose when the GH spike happens, classically at bedtime to reinforce the body's largest natural overnight pulse, and you keep food away from that window because a carbohydrate or fat load can blunt the GH response. The DAC form removes that lever entirely: with hormone elevated around the clock, there is no pulse to schedule and no trough to protect, which is convenient but also why the no-DAC camp frames the daily injections less as a chore and more as the price of control. Neither approach has outcome data behind it, so the choice still comes down to which trade you find more tolerable, not to a proven result. For how to think about that pairing concretely, see our CJC-1295 and ipamorelin dosage calculator, and for the molecule-versus-molecule question of which partner does what, see CJC-1295 vs ipamorelin.
How the ProtocolPlus community uses CJC-1295
Because the two forms are one peptide, there is no community "switch" data between them the way there is between two genuinely different compounds. What our data does show is how the CJC-1295 compound is tracked overall, and which dosing convention dominates, which is the useful signal here: it tells you how many people log this peptide and, by the size and frequency of their logged doses, which form the community leans toward.
In our app data, roughly 768 users in the community track CJC-1295, and the logging pattern is dominated by small, frequent doses, the signature of no-DAC-style use, with a median logged dose around 200 mcg. We are deliberately not inventing a precise "X percent use DAC vs no-DAC" split, because there is no clean head-to-head field to measure and fabricating one would be exactly the kind of number this site refuses to make up. The honest read is directional: the community convention leans no-DAC and pulse-aligned, frequently as part of a CJC-1295 plus ipamorelin stack, which lines up with the pulsatile-physiology argument above rather than the weekly-convenience one.
Safety, side effects, and legality: mostly shared, slightly favoring no-DAC
There is no large tolerability gap between the two forms, because the peptide is the same; the most-reported effects are also the same: injection-site reactions, transient flushing or headache, water retention or tingling that tracks with how hard GH and IGF-1 are pushed, and a theoretical concern about insulin sensitivity from sustained IGF-1 elevation. The small edge the no-DAC form gets on tolerability is indirect and theoretical, not a proven safety win: by clearing quickly and avoiding a multi-day plateau, it gives the pituitary regular troughs and avoids the chronic-elevation concern, which is the basis for it scoring a notch higher on safety in our scorecard. None of this is settled by human safety trials, which do not exist for either form at community doses. For the full side-effect breakdown and red-flag list, see CJC-1295 side effects; this page does not duplicate it.
On legality, both forms sit in the same place: CJC-1295 is not an FDA-approved drug, is sold for research purposes only, and is not approved for human use; it is also banned in sport by WADA as a growth-hormone secretagogue. That status does not differ between DAC and no-DAC, so legality is not a tiebreaker here.
The editorial scorecard (context, not a verdict)
The no-DAC form edges ahead at 60 to 53, and the radar shows exactly why: the two forms tie on evidence, effectiveness, accessibility, and cost (same peptide, same research-only status, similar price), and the no-DAC form wins only on the two dimensions where pulsatility matters, safety/tolerability and speed-to-pulse. This is a narrow, dimension-specific lead, not a knockout, and it reflects the on-paper physiology argument rather than any proven outcome.
Choose DAC if... / Choose no-DAC if...
Choose CJC-1295 with DAC if:
- Convenience is your hard constraint and once- or twice-weekly dosing is the only schedule you would realistically stick to.
- You want a steady, continuous GH and IGF-1 elevation rather than discrete pulses.
- You accept the trade-off of non-physiologic tonic stimulation in exchange for roughly a tenth of the injections.
Choose CJC-1295 without DAC (Mod GRF 1-29) if:
- You want GH release that mirrors the body's natural pulsatile rhythm and the lower theoretical desensitization risk that goes with it.
- You are willing to inject one to three times a day and time doses around sleep, fasting, or training.
- You plan to stack with a GHRP such as ipamorelin for a synergistic, pulse-aligned protocol.
- You want the form the research community most commonly converges on.
The honest verdict
There is no "better molecule" here because there is only one molecule. The decision is between a delivery technology and the rhythm it produces. If you value physiology and you are running a GHRP stack, the no-DAC form is the better-reasoned choice, and it is what the community leans on, which is why it edges our scorecard. If you simply will not inject daily, the DAC form exists for exactly that reason and is a legitimate convenience trade, as long as you accept that its steady elevation is the less physiologic option and that, like the no-DAC form, it has no human efficacy data behind it. The most useful move is not to pick a form off a comparison page but to be honest with yourself about adherence and to discuss any GH-axis experimentation with a qualified clinician, because nothing here is FDA-approved or proven in people.
For the molecule itself, see the CJC-1295 guide and CJC-1295 side effects. For the stack, see the CJC-1295 and ipamorelin dosage calculator and the molecule head-to-head CJC-1295 vs ipamorelin.
Frequently Asked Questions
Sources
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism, 2006. DOI 10.1210/jc.2005-1536. Retrieved 2026-06-19. https://academic.oup.com/jcem/article/91/3/799/2843248
- Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." Journal of Clinical Endocrinology & Metabolism, 2006. DOI 10.1210/jc.2006-1331. Retrieved 2026-06-19. https://academic.oup.com/jcem/article/91/12/4792/2656525
- U.S. Anti-Doping Agency / WADA. "Prohibited List: Peptide Hormones, Growth Factors, Related Substances (S2) - growth hormone secretagogues including CJC-1295." Retrieved 2026-06-19. https://www.wada-ama.org/en/prohibited-list
- U.S. Food & Drug Administration. "Compounding and the FDA: questions and answers (bulk drug substances; CJC-1295 not approved for human use)." Retrieved 2026-06-19. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- ProtocolPlus. "Community usage data: CJC-1295" (compounds.cjc-1295). First-party app data, 2026. ~768 users tracking CJC-1295; logging dominated by small, frequent (no-DAC-style) doses, median ~200 mcg. Usage signal, not a clinical efficacy ranking and not a precise DAC-vs-no-DAC split.